| abstract |
Due to the fact that rare cut endonucleases such as TALEN, Cas9, or Argonaute inactivate genes in the immune cells that encode antigen markers commonly found in both pathological and CD38 immune cells. Disclosed are methods for developing genetically engineered immune cells for immunotherapy that can comprise chimeric antigen receptors targeting antigen markers. |